Cancer 'turns off' important immune cells, complicating experimental vaccine therapiesAugust 31, 2012
Bethesda, MD-A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease. Although problematic for cancer treatment, these flawed dendritic cells could be valuable therapeutic tools for preventing the immune system from attacking what it should not, as is the case with autoimmune disorders and organ transplants.
"Immunotherapy of cancer has been an elusive research target that, though promising, never seems to 'get there,'" said José Alexandre M. Barbuto, Ph.D., from the Laboratory of Tumor Immunology, Department of Immunology, Institute of Biomedical Sciences at the University of São Paulo, in São Paulo, Brazil. "This study helps us to better understand the mechanisms by which tumors avoid immune recognition and rejection and may, therefore, teach us how to actually engage effectively the immune system in the fight against tumors, thus achieving much better clinical responses and, consequently, quality of life, in our therapeutic approaches."
To make this discovery, researchers obtained a small sample of blood from breast cancer patients, and from healthy volunteers. The blood cells were then separated and induced to become dendritic cells. Researchers then used these laboratory-generated dendritic cells to induce responses from other immune system cells, namely lymphocytes. While dendritic cells from the healthy donors induced vigorous lymphocytic responses, dendritic cells from cancer patients induced mainly the activation of a specific type of lymphocyte, a regulatory lymphocyte that works as a "brake" for other types of lymphocytes.
"Understanding why the immune system does not recognize and eliminate cancer is critical to developing effective immunotherapies to fight the disease," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Immunologists have been trying to unravel the answer to this question for decades and have realized that the problem is both on the immune system side, and because cancer cells appear to actively 'fly under the radar' avoiding immune system detection. This article offers insights into the underlying mechanisms regulating a key immune cell type, the dendritic cell, involved in initiating anti-tumor responses."
Federation of American Societies for Experimental Biology
Related Dendritic Cells Current Events and Dendritic Cells News Articles
Maternal obesity compromises babies' immune system at time of birth
Almost 60 percent of women of childbearing age in the United States are overweight or obese. Obesity is a major public health issue, and has been linked to health problems like heart disease, cancer and hypertension.
TSRI scientists identify interferon beta as likely culprit in persistent viral infections
Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute (TSRI) have found evidence that one of them, interferon beta (IFNβ), has an immune-suppressing effect that can help some viruses establish persistent infections.
Research shows how antibodies produce vaccine-like effect against tumors
The problem with traditional cancer treatments is that their effects don't always last: Stop the therapy and the disease may return.
Disrupting cancer pathway could enhance new immunotherapies
Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.
Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities
Weill Cornell Medical College researchers have shown for the first time that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development.
Understanding the body's response to worms and allergies
Research from The University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections.
Immunology: Macrophages as T-cell primers
New work by Ludwig-Maximilians-Universitaet (LMU) in Munich researchers demonstrates that macrophages can effectively substitute for so-called dendritic cells as primers of T-cell-dependent immune responses. Indeed, they stimulate a broader-based response.
Personalized melanoma vaccines marshal powerful immune response
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.
Strengthening the immune system's fight against brain cancer
When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy.
Genetic discovery provides clues to how TB may evade the immune system
The largest genetic study of tuberculosis (TB) susceptibility to date has led to a potentially important new insight into how the pathogen manages to evade the immune system.
More Dendritic Cells Current Events and Dendritic Cells News Articles